Affiliation:
1. Scientific Centre for Expert Evaluation of Medicinal Products
2. Scientific Centre for Expert Evaluation of Medicinal Products;
I. M. Sechenov First Moscow State Medical University
Abstract
Genetic diseases are often progressive in nature, and without proper treatment may result in disability or death. Difficulties with diagnosis of genetic diseases and lack of effective treatment are global public health challenges. Medical care for patients with genetic diseases is often confined to symptomatic and palliative care. Starting from the 2000s, great hopes have been placed on cell-based medicinal products (which are referred to as biomedical cell products in the Russian legislation) and gene therapy products. The aim of the study was to review current trends in the development of biomedical cell products for the treatment of genetic diseases. The paper focuses on cell-based products for the treatment of monogenic genetic diseases, such as severe combined immunodeficiency (SCID), recessive dystrophic epidermolysis bullosa (RDEB), beta-haemoglobinopathies, alpha-1-antitrypsin deficiency, haemophilia A, and Duchenne muscular dystrophy. Such drugs are being developed in many countries and are now entering preclinical and different stages of clinical trials. Products based on various types of viable cells, including differentiated cells, stem cells, induced pluripotent cells, as well as cells genetically modified ex vivo, may be developed for the treatment of one and the same disease. The main priority is the creation of such products that will obviate the need for replacement therapy or palliative care, and that will significantly increase life expectancy and quality of life.
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference44 articles.
1. Guttmacher AE, Collins FS. Genomic medicine – a primer. N Engl J Med. 2002;347(19):1512–20. https://doi.org/10.1056/NEJMra012240
2. Fischer A, Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet. 2008;371(9629):2044–7. https://doi.org/10.1016/S0140-6736(08)60874-0
3. Melnikova EV, Merkulova OV, Rachinskaya OA, Chaplenko AA, Merkulov VA, Olefir YuV, et al. Modern approaches to the assessment of the quality control of cell-therapy products. Biofarmatsevticheskiy zhurnal = Russian Journal of Biopharmaceuticals. 2016;8(4):35–46
4. Abbott A. Italians first to use stem cells. Nature. 1992;356(6369):465. https://doi.org/10.1038/356465a0
5. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science. 1995;270(5235):470–5. https://doi.org/10.1126/science.270.5235.470
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Updating preventive measures of children disability;Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics);2021-12-08
2. Application of biotechnology in recessive epidermolysis bullosa;Klinicheskaya dermatologiya i venerologiya;2021
3. Epidermolysis bullosa. Possible methods of treatment;Klinicheskaya dermatologiya i venerologiya;2021